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ABSTRACT

The most challenging complication after total joint replacement is the
periprosthetic joint infection (PJI). Staphylococcus aureus is a commensal
bacterium and a human pathogen. It is responsible for more than half of the
PJI. We demonstrated that synovial fluid has antimicrobial properties against
S. aureus and the iron restriction is one of the mechanisms used for the host
to prevent bacterial growth, and is even able to increase killing of S. aureus.
We have shown a clear role of transferrin as a restrictive factor in synovial
fluid that functions by iron starving the bacteria and sensitizing them to killing
by some other unknown factor, such as antimicrobial peptides. The
development of animal models would help to improve our understanding of
the pathogenesis of PJI. We also successful established an animal model of
PJI, which allows the temporal observation of disease progression and gives
the ability to track different bacterial mutants.
SUMMARY FOR LAY AUDIENCE
The most challenging complication after total joint replacement is the
periprosthetic joint infections (PJI). Staphylococcus aureus is the bacteria
responsible for more than half of the infections. We demonstrated that
synovial fluid has antimicrobial properties against S. aureus. The iron is the
most important nutrient used for bacteria and we found that the iron
restriction is one of the mechanisms used for the host to prevent bacterial
growth, and is even able to increase killing of S. aureus. We have shown a
clear role of one of the proteins in synovial fluid (transferrin) as a restrictive
factor in synovial fluid that functions sensitizing the bacteria for killing by
some other unknown factor, such as antimicrobial peptides. The
development of animal models would help to improve our understanding of
the PJI. We successful established an animal model of PJI, which allows the
temporal observation of disease progression.
KEYWORDS:

Staphylococcus, aureus, periprosthetic, infection, synovial

fluid, animal model.
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CHAPTER

1

BACKGROUND

1.1 Introduction to immune response

Microbes are ubiquitous throughout the gastrointestinal tract and on the
human skin, yet these bacteria rarely cause infection. Epithelial cells lining
the skin, respiratory, gastrointestinal, urogenital tracts provide a physical
barrier, which microbes are unable to cross. In addition to the physical
barrier these environments also produce several chemical barriers, such as
the low pH of the upper gastrointestinal tract. Moreover, human skin has a
high amount of salt and fatty acids, which prevent the growth of many
bacteria (1, 2). However, when these barriers are breached by some means,
pathogens will be able to bypass the physical and chemical barriers allowing
them to invade into the host tissues.
If pathogens are able to circumvent the initial barriers, they may then be
faced with the humoral component of innate immunity including the
complement system. The complement system consists of small soluble
proteins. When activated the complement system allow a proteolytic
cascade resulting in the formation of the membrane attack complex (MAC).
The MAC forms transmembrane channels leading to osmotic lysis of the
host cells (3).
Another mechanism of defense of many host tissues to infection is
known as colonization resistance, whereby commensal bacteria colonizing
the host compete with pathogens for nutrients and attachment sites. Iron is
an essential micronutrient for virtually all microorganisms owing to its wide
range of redox potentials. It serves as the catalytic center of enzymes
involved in critical cellular processes such as DNA synthesis and electron
transport. However, the amount of free iron in biological systems is low due
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to its tendency to form insoluble oxyhydroxides under aerobic conditions at a
neutral pH. The amount of iron available in the host environment is further
reduced by sequestration into proteins such as transferrin and lactoferrin,
virtually no free iron exists in living organisms (4, 5, 6).

1.2 Staphylococcus aureus as a pathogen

Staphylococcus aureus is both a commensal bacterium and human
pathogen. Many people are colonized with S. aureus and it is often present
asymptomatically on parts of the human body such as skin, skin glands, and
mucous membranes, including nares and guts of healthy individuals. It is
responsible for many different infections in the human population as
bacteremia,

infective

endocarditis,

skin

and

soft

tissue

infections,

pleuropulmonary, as well as osteoarticular and device-related infections (7,
8).
S. aureus, a member of the family Micrococcaceae, is a Gram-positive
coccus whose cells tend to occur either singly or if dividing cells do not
separate, form pairs, tetrads and distinctive irregular “grape-like” structures
(8, 9).
These organisms were first described and classified as Staphylococcus
in 1882 by the Scottish surgeon Sir Alexander Ogston (8, 10). Two years
later a German physician, Friedrich J. Rosenbach described 2 pigmented
colonies of Staphylococcus and proposed the nomenclature S. albus (Latin
for “white”) and S. aureus (Latin for aurum: “gold”) (11).
1.2.1 Epidemiology

S. aureus is one of the first described pathogens and it still is one of the
most common causes of infections in humans. It is important due to its
ability to cause infections as well as its capacity to adapt to diverse
environmental conditions. It can affect the bloodstream, skin and soft
tissues, and lower respiratory tract and can cause infections related to
medical instrumentation (8).
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One of the main issues associated with S. aureus is its ability to acquire
resistance against multiple antibiotics, complicating treatment. Resistance in
S. aureus emerged 2 years after the introduction of penicillin. The
semisynthetic methicillin antibiotic was developed in the late 1950s, and the
resistant strain (MRSA) was clinically identified in 1960 (8, 12).
The expansion of MRSA began in the late 1970s and this has turned
into a nonstop evolutionary journey. MRSA resistant to gentamicin emerged
in Europe and the United States (US), continued by Australia and Latin
America until in 2003, this microorganism was isolated in nearly 60% in US
intensive care units (12, 13).
In Canada, MRSA was first documented in 1964 and the first outbreak
occurred in 1978 at the Royal Victoria Hospital in Montreal. From the time of
its emergence until the 1980s, MRSA was essentially a hospital-acquired
pathogen. Today, these isolates of MRSA are called health care–associated
MRSA (HA-MRSA) and are highly resistant to most oral antibiotics (14).
Infections due to methicillin-resistant strains of S. aureus are associated
with higher mortality rates than infections caused by methicillin-susceptible
strains. In addition, they result in increased lengths of hospital stays as well
as associated health care costs. The prevalence and the epidemiology of
MRSA are constantly changing, with novel MRSA clones appearing in
different geographical regions. Therefore, continuous vigilance for MRSA
through monitoring the characteristics, host specificity, and modes of
transmission is required (8).
S. aureus is one of the major causes of hospital and communityacquired infections, resulting in serious consequences. Although many
actions to reduce healthcare-associated infections such as better antibiotic
selection, isolation of infected patients, skin and nose decontamination
treatment prior to surgery, and improved hand hygiene helped to reduce
MRSA infections, its prevalence is still increasing (12).

1.2.2 Resistance mechanism

The success of S. aureus as a human pathogen is attributable to its
ability to adapt. It has been able to evolve, acquiring resistance to nearly all
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antibiotics used to treat it (12, 15). S. aureus has wall glycopolymers,
including wall teichoic acid (WTA), peptidoglycan, lipoteichoic acid, and
capsular polysaccharides. These bacterial surface glycopolymers are
recognized by serum antibodies and a variety of pattern recognition
molecules leading to complement activation and host defense responses
(16).
Survival of bacteria depends of the biofilm formation (17). The biofilm is
a polymeric matrix that adheres to prosthetic material. It acts as a sanctuary
site where S. aureus is relatively protected from antimicrobial agents and the
host immune response. In addition, organisms within a biofilm generally
enter a stationary phase of growth and are thus much more resistant to
antimicrobial killing (7).
Understanding the development of staphylococcal biofilms is essential
to generate new treatment strategies for these infections. A known basic
model consists of three stages: 1) attachment, 2) accumulation/maturation,
and

3) detachment/dispersal. The use of

new technologies (e.g.

BioFlux1000 system) in recent studies allowed researchers to observe the
development of the S. aureus biofilm in real time. This consists of 5 stages:
attachment, multiplication, exodus, maturation, and dispersal (18).

Figure 1: Model of Staphylococcus aureus biofilms development (18).
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During growth and division, bacteria biosynthesize cell wall, which is a
polymer made up of the peptidoglycan as the principle building unit. The
peptidoglycan

is

composed

of

repeats

of

the

disaccharide

N-

acetylglucosamine (NAG)-N-acetylmuramic acid (NAM) with peptide stems
on the NAM unit. The peptide stems of neighboring peptidoglycan strands
are the points of crosslinking to give the mature cell wall. Synthesis of the
peptidoglycan backbone is carried out by the catalytic function of
transglycosylases, with transpeptidases - also referred to as penicillin
binding proteins (PBPs) - performing the crosslinking reaction. Coordination
of these reactions is an elaborate process, which ultimately results in the
cell-wall structure (17). The final step of the biofilm life cycle involves the
dispersal of cells with the ability to travel to distal sites to disseminate
infection. The mechanism by which S. aureus regulates this step is largely
mediated by the accessory gene regulator (agr) quorum-sensing system.
The agr system responds to cell density through the accumulation of signal
molecules, allowing for dispersal to occur once a threshold density is
reached, leading to bacteremia (18).
The penicillin resistance was reported in 1942, and the mechanism was
described in the mid-1940s based on an inducible beta-lactamase.
Methicillin was introduced in 1959 and two years later its resistance was
reported, beginning the “era” MRSA (12, 19).
The methicillin resistance is not due to beta-lactamase production but
due to the expression of an additional penicillin-binding protein (PBP2a) with
low affinity for beta-lactams (8, 9). PBP2a is encoded by chromosomal gene
mecA, located in a mobile genomic element known as the staphylococcal
cassette chromosome (SCC), in this case SCCmec. The mecA gene is
widely distributed among S. aureus as well as coagulase-negative
staphylococci. Therefore, it has been speculated that the methicillin
resistance determinant (mec determinant) is freely transmissible among
staphylococcal species (8, 20).
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1.3 Periprosthetic Joint Infections (PJIs)

Joint replacement is a highly effective intervention that significantly
improves the quality of life of the patient, relieves symptoms, restores joint
function, and improves mobility and independence in patients with severe
osteoarthritis, inflammatory arthritis, post-traumatic arthritis and many
conditions that affect the articular surfaces (21).
The number of arthroplasty procedures performed every year is
increasing, with a projected annual volume of more than 4 million cases by
2030 in the United States (22). As a result of the increasing volume of
primary procedures, there is an anticipated increase in revision arthroplasty.
The leading cause of revision surgery is a periprosthetic joint infection (PJI),
which is one of the most challenging complications after total joint
arthroplasty (23, 24). Recent studies estimate risk of infection to be
approximately 1-2% for both hip and knee arthroplasties (25).

Figure 2: The projected number of: a) Primary THA and TKA procedures in the United States
from 2005 to 2030. b) Revision THA and TKA procedures in the United States from 2005 to 2030
(22).

1.3.1 Prevention

The evolution of total joint arthroplasty in recent times in terms of design
and fixation of implants, has led to improvements in the control of
periprosthetic infection (26). The rate of this complication has been declining
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over the last two to three decades, mostly due to operating room
environments and operative techniques (27). The use of prophylactic
antibiotics and other precautions has helped reduce the prevalence of
clinically recognized periprosthetic infection from nearly 10% in the early
years in which arthroplasty was performed to less 1% in some series (26).
Despite this decline, periprosthetic infection is associated with immense
physiological, psychological, and financial costs (26). Numerous challenges
can be associated with the development of a PJI that may include the need
for multiple operations, a long period of disability for the patient, and
sometimes, a suboptimal result. The economic and psychological burden of
this complication leads to an ongoing effort to develop strategies to help
prevent and reduce its incidence to a minimum (28).
Pulido et al (28), in their study confirmed that some previously
implicated risk factors, such as wound drainage, hematoma formation, a
history of rheumatoid arthritis, prolonged operative time and urinary tract
infection, are still important predisposing factors for development of a PJI.
Other risk factors that were obtained from this analysis were prolonged
hospital stays, blood transfusions and obesity.
Table 1: Host risk factors classification.

Host risk factors of PJIs
Modifiable host risk

Active infection, alcoholism, cardiovascular disease, kidney

factors

disease, diabetes mellitus, immunosuppression, intra-articular
steroid, MRSA colonization, obesity, rheumatoid arthritis,
smoking.

Non-modifiable host
risk factors

Age,

gender,

bariatric surgery,

chronic anticoagulation,

previous joint surgery, previous joint infection, transplant.

Intra-articular steroid injections are widely used for the symptomatic
relief of osteoarthritis of the knee before elective total knee arthroplasty.
Cancienne et al (29) concluded that patients who received an intra-articular
injection between 0 and 3 months before surgery had an increased risk of
infection 3 months after the operation, compared to patients who had
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received intra-articular injections more than 3 months ago. Schairer et al
(30), obtained similar results about intra-articular corticosteroid injections in
the hips.
Diabetes mellitus has been considered a well-established risk factor for
surgical site infections (SSIs) following many surgical procedures. However,
it remains a controversial issue regarding of the development of PJIs after
primary total hip and knee replacement. In a high quality study utilizing the
Mayo Clinic Total Joint Registry (31), diabetes was reported not to be a risk
factor for PJIs when the variables were adjusted for age, gender, BMI, type
of surgery, ASA score and operative time. Martinez-Huedo et al (32)
obtained similar conclusions, demonstrating that the diabetes mellitus was
not associated with increased PJIs in patients undergoing THAs. Despite
this, The American Diabetes Association (33) supports the control of glucose
in all patients with diabetes mellitus and in those who receive therapies
associated with hyperglycemia, based on the evidence that the prevalence
of hyperglycemia in hospitalized patients is high and the Hospitalization
period offers the opportunity to diagnose unrecognized diabetes mellitus.
The screening of MRSA colonization in all patients before an elective
total joint arthroplasty (TJA) is a relevant topic in relationship to prevention of
PJIs. Several studies determined that high-level nasal carriage of S. aureus
was a significant independent factor with a relative risk of developing a SSI
and the quick, inexpensive, and simple nasal decolonization of the carriers
on admission is an effective technique to reduce the PJIs (34, 35).
1.3.2 Diagnosis and Classification

In order to diagnose a disease with certainty and determine its
prevalence, it is important to define the criteria for its diagnosis (26). The
different guidelines recommend that clinicians should suspect a PJI in
patients who have undergone a total joint arthroplasty (TJA) when they
present with any of the following signs and symptoms:


Persistent wound drainage over a joint prosthesis.



Acute onset of a painful prosthesis.
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Chronic

painful

prosthesis at

any

time

after

prosthesis

implantation, particularly in the absence of pain-free interval in
the first years following implantation (36).
Table 2: Musculoskeletal Infection Society (MSIS) criteria for a definite diagnosis of PJI (36).

1. A sinus tract communicating with the prosthesis; or
2. A pathogen isolated by culture from two separate tissue or fluid samples obtained from the
affected prosthetic joint; or
3. Four of the following six criteria exist:
a. Elevated serum erythrocyte sedimentation rate (ESR) or serum C-reactive protein
(CRP) concentration.
b. Elevated synovial white blood cell (WBC) count.
c. Elevated synovial neutrophil percentage (PMN%).
d. Presence of purulence in the affected joint.
e. Isolation of a microorganism in one culture of periprosthetic tissue or fluid.
f. Greater than five neutrophils per high-power field in five high-power fields
observed from histologic analysis of periprosthetic tissue at 400 times magnification.
However, it should be noted that PJI may be present even if fewer than four of these criteria
are met.

The evaluation of patients with a painful TJA begins with a through
history, physical examination, and joint specific radiographic imaging.
Multiple surgeries on the same joint, history of prior PJI, history of surgical
site

infections

of

the

same

joint,

comorbidities

resulting

in

a

immunocompromised state (i.e. diabetes mellitus, inflammatory arthropathy,
etc.) or patients with increased risks of skin barrier penetrations (i.e.
intravenous drug abuse, skin ulceration, chronic venous stasis, etc.) should
be considered at higher risk for PJIs. Physical exam findings suggestive of
PJIs include joint erythema, warmth, or large atraumatic effusion (37).
After the physical examination, the evaluation of the radiographic
studies is very important. There are a few non-specific changes suggestive
of chronic infection that may be apparent on plain radiographs. These
include periosteal reaction, osteolysis, or generalized bone resorption in
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absence of implant wear. The main role is to rule out other conditions such
as implants wear or fractures (26).
No single laboratory test has perfect sensitivity and specificity for
diagnosis infection. Screening test results that may suggest the possibility of
infection include elevation of the erythrocyte sedimentation rate (ESR) and
serum C-reactive protein (CRP) level more than three months after an
arthroplasty (26, 37, 38).
One of the most important tests in the evaluation for potential
periprosthetic infection is culture of the fluid aspirated from the joint (26).
Synovial fluid analysis should include a total cell count and differential
leukocyte count, as well as culture for aerobic and anaerobic organisms
(21). The American Academy of Orthopaedic Surgeons (AAOS) clinical
practice guidelines (39) suggest patients be off antibiotics for a minimum of
2 weeks prior to obtaining intra-articular culture.
PJIs are typically classified according to the timing of symptom
development and the mechanism of infection as acute, chronic and
hematogenous infection (37).
Table 3: PJIs classification (Time).

PJIs Classification (Time)
Acute

Within the first 4 weeks

Chronic

More than 4 weeks

Acute hematogenous

Secondary to another infection

Acute postoperative infections are a result of organisms that gained
access to the joint during the operation, or soon after it, from the overlying
skin or a draining wound. Infections of this type generally become
symptomatic within a few days or weeks after the arthroplasty. Late chronic
infections may result from organisms introduced during the operation, either
from the air, from surgical instruments, or from the implant itself. The lag
period is the time needed for the organisms to proliferate and induce
symptoms of the infection. Hematogenous infections are the result of the
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seeding of an arthroplasty site by organisms carried by the bloodstream
from a different site (26).
1.3.3 Treatment

Prosthetic joint infection remains a serious problem, despite modern
operative technologies, new implants and rigorous perioperative antibiotic
prophylaxis. The therapeutic goal must remain prevention, but the treatment
of established PJI aims for complete eradication of the infection with
maintenance of the joint function (40).
Once the diagnosis of periprosthetic joint infection is confirmed, the
characteristics of the infection are important. These include the duration of
symptoms, patient immune status and overall health characteristics, history
of periprosthetic joint infection in the current joint and all other joints, status
of any joint wound, joint function expectations, and characteristics of the
infecting organism. These data will dictate the surgical treatment selection
(26).
An essential component of the care of patients with PJI is strong
collaboration between all involved medical and surgical specialists (21).
Treatment algorithms are typically dependent on the classification (37).

1.3.3.1 Debridement, antibiotics, implant retention (DAIR)

Open debridement, antibiotics, irrigation and implant retention is an
option less invasive and that decreases morbidity and could be the solution
in patients with an early infection, within four to twelve weeks of surgery.
Recent studies demonstrated a rate overall proportion of success 70%
associated with DAIR in the treatment of infected THAs (41).
DAIR should be considered an urgent procedure, as the time period
from the onset of symptoms until the operation has been reported to be an
important factor affecting the success of the procedure. Type of infecting
organism, duration of symptoms before intervention, type and duration of
antibiotic therapy, age, presence of underlying inflammatory conditions,
exchange of modular components, and the presence of preoperative
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comorbidities are known factors that affect the outcomes of DAIR (42, 43).
Kunutsor et al (44), in their results showed that a longer duration between
onset of symptoms to DAIR (≥ 21 days) is associated with lower infection
control compared with a shorter duration (< 21 days).
Patient medical comorbidities are one consideration prior to DAIR;
however, the effect of individual medical comorbidities on failure of DAIR is
not clear (35). Obesity has been associated with the risk of PJI, however, no
direct correlation has been found between the failure of DAIR treatment and
high BMI when this is taken as a continuous variable (45).
Compromised host immunity may lead to inferior outcomes. Diseases
such as diabetes mellitus and inflammatory arthritis increase the risk of
primary PJI; however, their association with failure of DAIR is less clear.
Although an optimized host maximizes the chances of success for DAIR;
individual comorbidities by themselves do not appear to provide a
contraindication to the procedure (44, 45).
Fink et al. (46), had successful outcome in 71.6% of patients overall,
with 82.1% for early postoperative infections and 57.1% for acute
hematogenous infections.
Regarding of analyses by specific infecting organism, the evidence
suggests similar infection control for Gram negative and Gram positive
bacteria. Further analysis confirmed higher infection control for streptococcal
infection (89,5%) compared with staphylococcal species (75%) (44).
Triantafyllopoulos et al. (47), concluded that infection by Staphylococcus
aureus, particularly methicillin-resistant Staphylococcus aureus (MRSA),
shown to be associated with high failure rates after DAIR. According that,
DAIR should be discouraged when the chance of failure without removing
the implant is very high. Therefore, chronic PJIs should be considered an
absolute contraindication of this procedure, as a fully developed mature
biofilm with the presence of "persister cells" excludes the possibility for cure
without removal implant (48).
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1.3.3.2 One stage exchange

One stage exchange arthroplasty was originally described by Buchholz
et al. (49) and is used in several centers today, particularly in Europe. Onestage exchange arthroplasty is similar to the two-stage procedure but the
interval between removal of the arthroplasty and reimplantation of a new one
is only a few minutes. The benefits are only one anesthetic procedure,
shorter hospitalization, less cost and earlier recovery (50, 51).
In addition, strict preoperative, intraoperative and postoperative criteria
must be considered to indicate this management. The correct patient
selection, identification of bacteria preoperatively, aggressive soft tissue
debridement, meticulous removal of the prior cement material and implants,
specific postoperative antibiotic regimens are important for success of this
procedure. It is essential to have an experienced surgical team and an
infectious disease specialist (microbiologist) (51).

Figure 3: Diagram of the necessary prerequisites to fulfil a one-stage exchange revision joint
replacement (52).
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There are several contraindications of a 1-stage exchange, including,
but not limited to (40, 52):
 Unidentified bacteria preoperatively;
 Failure of >2 previous 1-staged procedures;
 Infection involving the vascular/neurovascular bundle;
 Lack of appropriate antibiotics;
 Infection with a highly virulent organism.

Generally, the surgical technique consists of open aggressive
debridement with removal of all components and cement, during which
multiple samples are sent to microbiology before administration of antibiotics
and the joint is irrigated with hydrogen peroxide and an antiseptic solution,
and pulsatile lavage. The wound is then soaked in aqueous antiseptic
solution and the wound edges are approximated. The patient is then
redraped, the surgical team rescrubs, and new instruments are used. After a
further lavage, implantation of a new prosthesis is performed using
antibiotic-loaded cement (ALC) according to known sensitivities at a volume
of 5% of the total weight of cement powder. Postoperatively, patients
continue antibiotic therapy tailored to the sensitivities of intraoperative
cultures for at least 6 weeks until inflammatory markers (CRP, ESR) and
nutritional markers such as plasma albumin concentration return to stable
limits. The change from intravenous to oral therapy is affected as soon as a
full organism sensitivity profile is obtained and after consultation with
infectious diseases team (52, 53).
Infection control using a single-stage strategy in selected patients is
achieved in 67% to 95% of patients (53). The patients must be conscientious
of the possible risks associated with one-stage exchange, for example: risk
of recurrent infection rate 10-15%; reoperation for hematoma, wound
debridement or persistent infection; and risk of intra and post-operative
fracture (40).
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1.3.3.3 Two stage exchange

Two-stage reimplantation was first described by Insall et al. (54).
Currently, it is the gold standard for the treatment of a chronic PJI. This
involves a minimum of 2 surgeries for the patient, the first to remove the
infected prosthesis, extensive debridement of nonviable tissues, irrigation
and implantation of a temporary antibiotic-impregnated cement spacer; and
once the infection is eradicated, and a second surgery to place a new
prosthesis. Antibiotics are administrated based on the sensitivities of the
infecting organisms (55, 56).
There are two relevant topics about the two-stage exchange, first is
antibiotics-impregnated static cement spacer vs. articulating cement spacer;
and second is the duration of therapy systematic antibiotics and the timing of
reimplantation.
There is no clear consensus on the ideal type of spacer for
management of PJIs of the hip and knee. The goal of the spacer is to
preserve the joint space and reduce the soft tissue contracture while
delivering

high

doses of

antibiotics.

Static spacers are

generally

recommended for cases with massive bone loss, lack of functional collateral
ligaments, extensor mechanism disruption and the need for soft tissue
reconstruction, while general functional improvement is expected with
articulating spacers. The results for infection eradication are similar in
individual studies (55). Park et al. (57) concluded that the articulating
spacers have been shown to be associated with improved range of motion,
better function, and also with the ability to facilitate ease of dissection at the
second stage. However, few data are available on the incidence and type of
spacer-related problems. Struelens et al. (58) found that there was a 57%
incidence of spacer-specific problems, the most frequent being spacer tilting
and medial lateral translation. Lanting et al. (59) found a spacer complication
rate of 8.4%, but they did not include lateral and posterior subluxation cases
due to these complications were common, probably secondary to
inadequate soft tissue tensioning and incorrect position of the spacers. In
addition, articulating spacers typically come in a limited number of sizes and
have less constraint than the primary knee arthroplasty removed.
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Regarding the duration of therapy of systematic antibiotics and the
timing of reimplantation, Insall et al. (54) suggest a protocol prolonged of
intravenous antibiotics between the two stages of surgery (6 weeks).
Several recent studies have questioned the standard, prolonged antibiotic
therapy used in two-stage revision procedures for PJI. Infection and surgical
trauma can cause the blood supply to the periarticular tissue to be
attenuated, which prevents antibiotics administered systemically from
reaching the desired site of action (60). Antibiotic-loaded cement spacers
can maintain levels of antibiotics that are effective against infection for up to
4 months following resection arthroplasty (61). Furthermore, a shorter
course of intravenous antibiotic therapy decreases the likelihood of systemic
toxicity and may reduce the emergence of drug-resistant organisms (62).
The short period of antibiotic treatment has a successful eradication rate
similar to that reported with longer regimens and is associated with less
morbidity (61, 62).
1.3.4 MRSA Periprosthetic Joint Infections

The management of infection after total joint replacement has been
compounded by the emergence of organisms with resistance to some
antibiotics (63).
In recent years, there has been a worrisome increase in number of PJIs
caused by MRSA. According to recent studies, more than one half of PJIs
treated in some institutions are caused by methicillin-resistant organisms.
Approximately 47% of S. aureus clinical isolates in the United States are
methicillin-resistant (64).
Patients with PJIs is associated with a higher number of readmissions,
lengthier of hospitalization, an increased number of clinic visits and poor
clinical outcomes (65). The impact of these factors imply that the costs of
treating PJI caused by these organisms are higher compared to infections
caused by methicillin-sensitive organisms (64).
Treatment of prosthetic joint infection creates an economic burden for
the patient and healthcare facility with estimated costs higher than a
$100,000 per episode (65, 66). Parvizi et al. (64) found that the

INVESTIGATING THE PATHOGENESIS OF S. AUREUS IN THE PERIPROSTHETIC JOINT INFECTIONS

17
management of MRSA PJI has a higher cost due mainly to the length
hospital stay. Similarly, the cost of treating intensive care unit admissions
was also found to be higher compared to infections caused by methicillinsensitive organisms.
MRSA has become a prominent cause of infection in hip replacement,
typically presenting early, reflecting its high virulence. Treatment is often
prolonged, with a high rate of infection of the implant (63). Retention of the
total hip or knee components, regardless of whether the components were
well-fixed, generally was not successful when the infecting organisms were
S. aureus or S. epidermidis that were resistant to currently available
intravenous antibiotic therapies. The most successful treatment protocols
include excision of all components, repeated surgical debridement, removal
of all components and cement, and waiting for longer periods before
reimplantation (a minimum of 5 weeks for knee arthroplasties, and 8 to 12
weeks for hip replacements). In addition, the use of intravenous vancomycin
and oral rifampin is indicated (62).
Given the increasing number of THA and TKA required for an aging
population, infection with MRSA has implications for the future success of
joint replacement surgery, the quality of life and of mortality (63).
1.4 Synovial Fluid: Role in Periprosthetic Joint Infections

Osteoarthritis (OA) is a common disease that affects joints by causing a
breakdown of cartilage and synovial fluid that results in increased wear,
pain, inflammation and reduce mobility (67, 68).
The synovial fluid is the body´s natural synovial joint lubricant and it has
been established which are its changes in OA (67, 68). Protein
concentration, protein constituent fractions, osmolality, thermal stability, HA
concentration plays an important role in OA (68). However, its role in the
development of periprosthetic joint infections it is not well known.
Innate immunity against bacterial pathogens is present in many body
fluids, including saliva, pleural, and peritoneal fluids (69). Although dental
procedures are not risk factors for subsequent total hip or knee infection
(71), occult bacteremia is estimated to occur in patients as often as 80% of
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the time following routine dental or gastrointestinal manipulations (70, 71).
The relatively infrequent occurrence of septic arthritis in this setting suggests
that although synovial joints frequently may be exposed to transient
bacteremia events, synovial fluid likely possesses antimicrobial properties
sufficient to the joints are able suppress these episodes and prevent
progression to a clinically detectable septic arthritis.
The evidence suggests that in addition to the adaptive defense of the
body’s cell-mediated immune response, the knee joint possesses inherent
defense mechanisms against infection. The synovial fluid may contribute to
a joint’s innate defense against certain microbial infections. However, the
specific immunologic properties and protective mechanisms of synovial fluid
against common gram-positive bacterial pathogens that are encountered
clinically remain unknown (72).

1.5 Animal Model for study of Periprosthetic Joint Infections

The increase in the number of periprosthetic infections in recent years
and their consequent devastating results with an increase in morbidity and
mortality, as well as high patient dissatisfaction and poor quality of life, has
led to the development of animal models for the study of periprosthetic
infections. Once established, such models are likely to transform our
understanding of the pathogenesis of PJI and lead to novel treatments (73).
Carli et al. (74), in their recent study proposed four 4 standardized
criteria that animal models should meet to be considered as clinically
representative of PJI:
1.

Musculoskeletal and immunological properties comparable to those in

humans.
2.

The implant utilized should be made of clinically relevant materials, bear

load, and effectively reproduce the periprosthetic environment.
3.

The model should utilize clinically relatable bacteria and demonstrate

biofilm formation on the implant surface.
4.

The model methodology should include quantitative measurements of

bacteria, biofilm, and host immune response.
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The use of animals in research, teaching, and testing is acceptable only
if it promises to contribute to understanding of fundamental biological
principles, or to the development of knowledge that can reasonably be
expected to benefit humans or animals. A continuing sharing of knowledge,
review of the literature, and adherence to the Russell-Burch "3R" tenet of
"Replacement, Reduction and Refinement" are also requisites. Those using
animals should employ the most humane methods on the smallest number
of appropriate animals required to obtain valid information (75).

1.5.1 In vivo molecular imaging in animal models

In vivo molecular imaging in animals is an expanding discipline in
biomedical research in the current post-genomic era. The advancement in
molecular and cellular techniques, the increased numbers of animal models
and the development of novel imaging systems have converted the noninvasive in vivo imaging in an advantage tool over conventional
cytology/histology microscopy techniques, which involve chemical fixation of
removed tissues from which it can be difficult to generate quantitative data
(76).
It is currently possible to develop non-invasive in vivo imaging of
specific molecular and cellular mechanisms; to simultaneously monitor
multiple molecular events; to track specific molecular targets; to optimise
drug and gene therapy; to visualise drug effects at the molecular and cellular
level; and to assess disease progression (77).
In addition, obtaining in vivo longitudinal imaging of the same animal
model at multiple time points can achieve more valuable information than
would be obtained from multiple individual models, avoiding the sacrifice of a
large number of experimental animals. In these systems, the animal acts as
its own control and the dynamic data show the progressive biological
changes and the therapeutic response (78).
In recent years, there has been considerable progress in the
development of non-invasive small animal in vivo imaging technology. The
most popular techniques utilised by researchers are Magnetic Resonance
Imaging

(MRI),

Computed

Tomography

(CT),

Positron

Emission
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Tomography (PET) and optical imaging (bioluminescence and fluorescence)
(78).
1.5.1.1 Optical Imaging

This imaging modality produces excellent data from organs and
structures close to the skin surface in small animals. This technique employs
quantitative light emission i.e. photons to obtain measurements of relevant
biological parameters, including proteins and nucleic acids within individual
living cells. To detect low levels of light or photons, a very sensitive charge
coupled device (CCD) detector is used. The CCD detector is capable of
detecting light near-infrared range (NIR). There are two main forms of optical
imaging, fluorescence imaging (FLI) and bioluminescence (BLI) (79).
In FLI, the visible light (395 to 600 nm) is used to excite fluorescence
within the subject and a camera or fluorescent microscopy system detects
the emitted light from the region of interest within the subject. The strategy is
to fluorescently tag the cells, tissue or molecules under investigation with
substances known to fluoresce. In the recent past, a popular choice has
been the green fluorescent protein (GFP) which is derived from jellyfish
Aequorea victoria. The wildtype GFP emits light at 509 nm, while its variant
EGFP has a longer emitting wavelength and is 35-fold brighter. Another
popular fluorescent protein is the red fluorescence protein (RFP) DsRed, a
faster maturing and more soluble variant of reef coral protein from the
Discosoma species which allows more rapid appearance of red fluorescence
and reduce the aggregation. Currently, new fluorescent probes were
developed from a genetic modification of RFP such as mBanana, td-Tomato,
mTangerine, mStrawberry and mCherry with longer emission wavelength
and greater stability (78).
In BLI, light emission does not require excitation of the reporter. Light
emission originates from an exergonic catalysis reaction of the substrate
which releases photons of visible light. One common approach used in
animal models is transfection of one of the luciferase family of photoproteins through tail vein injection just prior to BLI (79).
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The luciferase can be isolated either from the sea-pansy (Renilla
reniformis) or from the North American firefly (Photimus pyralis).
Furthermore, its expression can be controlled so that it is expressed only
when required. Cells expressing luciferase can be easily identified through
their emission of light in the range from 400 to 620 nm (79).
The main advantage of BLI over FLI is its capability to detect very low
levels of light signal. In addition, in FLI, the external light source required for
fluorochrome excitation could also generate background autofluorescence
from animal tissues. However, an advantage over BLI is that FLI does not
require administration of a substrate for visualisation. This overcomes the
potential issues of difficult intravenous access in small animals (78).
1.6 Project rationale

Periprosthetic infection is a leading cause of failure after total hip and
knee arthroplasty. Infections remain a challenge for both patients and
surgeons to treat and occur in approximately 1% of cases. It's still not clearly
understood what the composition of the synovial fluid is of patients about to
undergo these procedures. Owing to the increasing prevalence of resistant
bacterial strains, and other factors, the likelihood of successful eradication of
a chronic infection continues to decline, which is very challenging for the
patient and surgeon and very expensive for a healthcare system with
diminishing fiscal resources.
A better understanding of the environment in which the infection
causing bacteria is growing could help lead to improved treatment strategies
in the future.
This current study will serve as the foundation for a body of work, which
is the result of a multidisciplinary collaboration with orthopaedics,
microbiology and medical biophysics to work to solve the most challenging
clinical problem facing arthroplasty patients and surgeons from the standpoint of treatment and clinical outcomes.
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1.7 Research objectives

1.7.1 General objectives

1. Study the behavior of S. aureus in the synovial fluid for a better
understanding of these infections in the joints and leading to novel
strategies in the treatment of periprosthetic joint infections.
2. Develop a murine model of prosthetic joint infection that allows
future studies for investigating the parameters involved in S. aureus
infections after total joint replacements.
1.7.2 Specific objectives

1. Determine the effect of synovial fluid on S. aureus growth in-vitro.
2. Determine which specific factors serve to affect bacterial growth in
synovial fluid.
3. Evaluate the behavior of three different strains of S. aureus into the
mouse knee joint after surgical implanted of Kirschner wire.
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CHAPTER

2

MATERIALS AND METHODS

2.1 SYNOVIAL FLUID

2.1.1 Ethics statements

Prior to patient enrollment for the synovial fluid collection, this research
was approved Health Sciences Ethics Board of University Western Ontario
and Lawson Research Institute. An informed consent was obtained from
each patient prior to the surgery.
2.1.2 Synovial fluid collection

The synovial fluids samples were obtained from ten patients undergoing
elective primary total knee replacement for treatment of symptomatic endstage osteoarthritis. All samples were collected under sterile conditions by
the same surgeon in the operating room at University Hospital. As per
standard of care, to minimize the possibility of contamination with blood, a
tourniquet was applied, and skin incision was carried out. Once the extensor
mechanism and joint capsule were exposed, a sterile 18-gauge needle and
20 cc syringe were used. The needle was introduced into the joint
anteromedially and fluid was withdrawn from the knee. The samples were
then analyzed in the Heinrichs Lab at Siebens Drake Research Institute of
University Western Ontario.
Patients with severe medical comorbidities, a diagnosis of inflammatory
arthropathy (i.e. rheumatoid arthritis, gout) or a diagnosis of fibromyalgia
were excluded.
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The samples of synovial fluid collected were labelled as sample 1, 2,
etc. No identifiable data were retained with the samples. After analysis was
complete, the samples were destroyed.
Patients were monitored at their standard follow-up appointments with
the surgeon for adverse events and complications according to the standard
of care at our institution. There was no follow-up monitoring for this study.
2.1.3 Synovial fluid preparation

After sterile collection in the operating room at University Hospital, the
synovial fluid samples were transported to Dr. Heinrichs Lab at the Siebens
Drake Research Institute of University Western Ontario.
These were centrifuged at 5000 rpm for 10 minutes within 12 hours of
collection to remove any possible blood cell contamination. The cell-free
supernatant of synovial fluid was aspirated and transferred to cryovials using
sterile technique. The samples then were transferred to a -80°C freezer for
storage until final analysis.
The samples that did not centrifuge to a clear supernatant were
discarded and excluded from analysis.
2.1.4 Bacteria strain and culture conditions

S. aureus strains; UAMS-1 (osteomyelitis isolate) (80), USA300
(plasmid cured) (81), USA300 graS (16), SH1000 (82), RN6390 (83),
Newman (84), and Newman sfasbn (85) were used in this study (Table
4). Bacteria were routinely cultured at 37°C in tryptic soy broth (TSB) (Difco)
with shaking or on TSB agar (1.5% w/v). When necessary bacteria were
cultured in the presence of 50 µg/mL kanamycin, 4 µg/mL tetracycline, or
300 µg/mL spectinomycin.
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Table 4: Bacteria strains used in Synovial fluid assays
Strain

Description

Source

UAMS-1 WT

UAMS-1; Osteomyelitis isolate

Laboratory stock

USA300 WT

USA300 LAC; MRSA cured of antibiotic

Laboratory stock

resistance plasmids


graS

Derivative of S. aureus USA300 with graS

Flannagan. 2018 (16)

created by pKOR mutagenesis

SH1000

WT S. aureus strain derived from 8325-4

Horsburgh. 2002 (82)

RN6390

Prophage-cured wild-type strain

Peng. 1988 (83)

Newman

Wild-type clinical osteomyelitis isolate

Duthie.1952 (84)

sfasbn

Derivate of S. aureus Newman with sfasbn

Beasley. 2009

deletion

(85)

2.1.5 In-vitro synovial fluid analysis

2.1.5.1 Synovial fluid growth assay

Synovial fluid samples from different donors were thawed and in-vitro
growth analyses were performed using various S. aureus strains. Overnight
cultures of each strain were grown in TSB and then diluted to and OD600 of
1.0 in saline. Tubes containing a series of 2 fold dilutions of the synovial fluid
in RPMI medium were inoculated with 10L of the OD=1 suspension for
each strain to achieve a starting OD600 of 0.01 for each tube.
Two common restriction mechanisms employed by the host are the
production of antibacterial proteins and limitation of bacterial access to
nutrients such as iron. By inactivating antibacterial proteins such as the
complement system or by adding exogenous iron sources we can
investigate whether these specific immune mechanisms are active in
synovial fluid. For these reason, in certain experiments exogenous iron was
added to the synovial fluid in the form of 25M FeCl3; and in some cases the
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synovial fluid was heated at 55° C for 1 hour to inactivate heat sensitive
proteins prior to dilution in RPMI.
After 37° C incubation for 24 hrs, the bacteria were serially diluted and
plated on tryptic soy agar (TSA) and incubated overnight at 37° C to
determine the number of colony forming unit per ml (CFU/mL).

2.1.5.2 Bacterial viability assay

Bacterial viability assay was performed in saline solution containing
synovial fluid with and without additional iron to determine if the synovial
fluid can kill various strains mutants of S. aureus rather than simply
preventing growth. Synovial fluid samples from different donors were thawed
and tubes containing either 20% or 50% of synovial fluid in saline solution
were prepared. Tubes containing saline without synovial fluid were included
as a negative control and when necessary 25mM FeCl 3 was added to the
synovial fluid samples. Overnight cultures of all of the strains tested were
grown in TSB then diluted in saline and the samples were inoculated at an
initial OD600 of 0.01. All of the samples were plated on TSA at time 0 to
confirm all samples started with an equivalent number of CFU/mL. The
samples were then incubated at 37°C for 24 hours after which they were
again plated on TSA to determine the number of CFU/mL remaining.

2.1.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) / Mass Spectrometry

Synovial fluid samples were thawed and diluted to an initial
concentration of 20% in saline. Two-fold dilution series were then generated
and mixed at a 1:1 ratio with Laemmli and the samples were boiled for 10
minutes. After cooling, 7L of each dilution was loaded and ran on a 12%
sodium dodecyl sulfate polyacrylamide gel in Tris-glycine buffer at 150V,
and 500mA for 90 minutes. Upon completion the gel was removed from the
dock and stained overnight with InstantBlue. After staining the gel was
taken to the department of biochemistry where an automated spot picker
was used to isolate the individual bands from the gel. These samples were
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then sent for digestion and matrix associated laser desorption ionizationmass spectrometry (MALDI-MS) by the Department of Biochemistry.
2.1.5.4 Centricon filtered synovial fluid growth assay

Synovial fluid samples from different donors were thawed and diluted in
RPMI containing either 20% or 5%. The synovial fluid samples were filtered
using an Amicon ultra centrifugal filter units with a 30 kDa MW cut‐off for 20
minutes. The filtrate containing proteins below 30 kDa and the concentrate
containing proteins above 30 kDa were re-suspended in their initial culture
volume. The filtered samples along with unfiltered control were used to
make a series of dilutions (20, 10, 5, 2.5, 1.25, 0,612 and 0 %) of the
synovial fluid. These tubes were inoculated at an initial OD600 equivalent
0.01 and after 24 hours incubation at 37°C the samples were plated on TSA
to determine the number of CFU/mL.

2.1.5.5 Statistical Analysis

Data are presented as the mean ± SD. All statistical analyses and
graph production were done through GraphPad Prism (GraphPad Software,
La Jolla, CA). Data were analyzed using unpaired t-tests or a one-way
analysis of variance with either Dunnett’s or Bonferroni’s multiple
comparison test as indicated. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

2.2 ANIMAL MODEL OF S. AUREUS PERIPROSTHETIC JOINT
INFECTION (pilot study)

2.2.1 Ethics statements

The animal protocol was reviewed and approved by the University of
Western Ontario Animal Use Subcommittee, according the guidelines set
out by the Canadian Council on Animal Care. The study was conducted in
strict accordance with the recommendations in the Guide by the Canadian
Council on Animal Care.
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2.2.2 Mice

Three female C57BL/6 mice (Charles River Laboratories, Canada) (12
weeks old) were used for periprosthetic joint infections animal models.

2.2.3 Bacterial strains

Three different S. aureus subsp. aureus strain USA300 were used in
animal models: USA300 wild-type, fhuCBG::ermC mutant strain (86) and
purR::ΦNΣ mutant strain (87) (Table 5).
Table 5: Bacteria strains used in animal models
Strain

USA300 WT

Description

Source

USA300 LAC; MRSA cured of antibiotic resistance

Laboratory

plasmids
fhuCBG::ermC

purR::ΦNΣ

stock

Derivate of S. aureus Newman with fhuCBG operon

Speziali.

deletion derivative of S. aureus

2006 (86)

Strain USA300 LAC containing a transposon insertion

Goncheva.

in the purR gene

2019 (87)

2.2.4 Mouse surgical procedures

Mice were anesthetized with isoflurane in a laminar flow hood. The mice
were placed on their back and the operative leg was maximally flexed at the
knee. Using a #15 scalpel blade, an anterior longitudinal midline incision
was made centered over the knee. A subsequent incision was made just
medial to the patella and extensor mechanism. The extensor mechanism
was subluxated laterally and the distal end of the femur was identified. A 25gauge needle was used to open the femoral canal. A medical-grade
stainless steel Kirschner wire (K-wire) (0.6 mm) was surgically placed into
the femur in a retrograde fashion up to the greater trochanter and cut with 1
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mm protruding into the knee joint space. Surgeries were performed by
myself under sterile conditions.
S. aureus (2x105 CFU in 2 μL saline) were inoculated into the joint
space using a Hamilton syringe. The patella was relocated and the surgical
incision was closed with Vicryl 5-0 sutures.
A high-resolution X-ray was taken immediately after the surgery to
ensure proper placement of the implant. Buprenorphine (0.1 mg/kg) was
administered subcutaneously every 72 hours as an analgesic for the first 6
postoperative days.

A

B

C

Figure 4: (A) Mouse surgical procedure: The knee was maximally flexed and a 3-5 mm
longitudinal incision was made centered over the knee. Medial parapatellar arthrotomy was
performed and a 27-gauge needle was used to create an entry portal to distal femur. (B) and (C)
Imaging: High-resolution X-ray was taken after the surgery to ensure proper placement of the
k-wire implant.

2.2.5 Quantification of in vivo S. aureus (In vivo bioluminescence
imaging)

In vivo bioluminescence was performed with the IVIS imaging system at
the Robarts Research Institute (London, ON, CA) at 7, 14, 21, 28, 35 and 42
postoperative days.
Mice were anesthetized with isoflurane. Data are presented on color
scale overlaid on a grayscale photograph of mice and quantified as total flux
(photons/s) within a circular region of interest with Living Image software.
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2.2.6 In-vitro growth analysis

The mice were sacrificed at postoperative day 42. The implants were
removed and the proximal aspect of the tibia, the distal aspect of the femur
and implant were cut into small pieces and placed into sterile, 5-mL
centrifuge tubes (Eppendorf) containing 2 mL of 4°C PBS + 0.1% TritonX100 solution. The contents were homogenized for 5 minutes (Bullet
Blender; Next Advance) at setting 16, diluted in 4°C TSB, and then plated by
duplicate on TSA to determine the number of CFU/mL in the periprosthetic
tissues and implant. These samples also were plated on TSA with
chloramphenicol, which allows us to determine the bacteria recovered still
carry the bioluminescence genes and the associated chloramphenicol
resistance marker.
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CHAPTER

3

RESULTS

3.1 S. AUREUS GROWTH IN SYNOVIAL FLUID

3.1.1 S. aureus UAMS-1 grows poorer in synovial fluid than S. aureus
USA300

To initially explore the effect of synovial fluid on the growth of S. aureus
in-vitro growth assays were performed using two strains of S. aureus,
USA300 and UAMS-1. The control specimen with no synovial fluid
demonstrated exponential growth as expected. In contrast, bacterial counts
in all of the synovial fluid specimens were decreased compared to controls.
Although, USA300 strain demonstrated a significant decrease (**P<0.01,
***P<0.001, ****P<0.0001) of CFU/ml in all concentrations of synovial fluid,
no bacterial death was demonstrated (Figure 5A). In contrast, the UAMS-1
strain demonstrated greater sensitivity to the synovial fluid. A synovial fluid
concentration of 2.5% or higher was sufficient to significantly reduce growth
compared to the control (**P<0.01). Moreover, concentrations of 5% or
higher prevented visible growth and in some cases resulted in bacterial
death (***P<0.001, ****P<0.0001) (Figure 5B). Taken together, these data
indicate that synovial fluid has antimicrobial properties and S. aureus UAMS1 is more sensitive than S. aureus USA300.
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A)

B)

Figure 5 In-vitro growth analysis in synovial fluid. In (A), USA 300 strain was used to inoculate
tubes containing different concentrations of synovial fluid in RPMI and the CFU/mL of bacteria at 24
hours was determined N=3. In (B), similar in-vitro growth assays were performed using UAMS-1 strain
N=6. Statistical significance was determined by Dunnett’s multiple comparison test where *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001. Dashed lines the initial CFU/mL inoculated into each tube.

3.1.2 Iron limitation contributes to the ability of synovial fluid to restrict
the growth of S. aureus

The next objective was to determine the mechanism of bacterial
restriction in synovial fluid. To this end in-vitro growth curves were
performed in RPMI with synovial fluid that had either been heat inactivated
(H.I.) or with the addition of 25uM FeCl 3 (the latter serves to saturate the iron
sequestering capacity of lactoferrin/transferrin). After 24 hours incubation at
37°C, we found the additional iron significantly increased bacterial growth in
10% and 20% synovial fluid samples compared to the control specimen
(**P<0.01). No significant differences were found in 5% synovial fluid
concentration or lower. The heat inactivation did not demonstrate significant
variations in bacterial growth compared with the control (Figure 6). This
together shows that iron restriction is one of mechanisms used by the host
to prevent bacterial growth in synovial fluid.
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Figure 6: UAMS-1 growth in treated synovial fluid. As before growth assays were performed with
synovial fluid diluted in RPMI. The synovial fluid was either Heat inactivated at 55°C for 1 hour or
exogenous iron was added in the form of 25M FeCl3 prior to inoculation with S. aureus UAMS-1.
Tubes were incubated at 37°C for 24 hours and the CFU/ml was determined. Statistical significance
was determined by Bonferroni’s multiple comparison test where *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001 N=3. Dashed line indicates the CFU/mL inoculated into each tube.

3.1.3 Iron restriction in synovial fluid increases killing of S. aureus
UAMS-1

Given that S. aureus UAMS-1 growth decreased due to iron restriction,
the next step sought to determine whether the iron restriction simply
prevents bacterial growth or if it can also contribute to the killing of UAMS-1.
Bacterial viability assays were performed in tubes containing saline with
20% synovial fluid with and without the addition of exogenous iron. The
synovial fluid resulted in an obvious killing of UAMS-1 compared to saline
alone controls, but the addition of FeCl 3 did improve bacterial viability
(Figure 7A and B). However, the addition of FeCl 3 to synovial fluid did not
restore viability to the level of the saline alone controls. It is worth noting that
when the samples were sorted by each individual donor the statistical
analysis showed no significant differences in survival due to a low number of
replicates for each donor (Figure 7A). Meanwhile, a combined analysis
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demonstrated a statistically significant increase of bacterial survival in the
samples with iron additional compared with the synovial fluid alone
(****P<0.0001) (Figure 7B). This confirms that iron is restricted in synovial
fluid and this restriction results in increased killing of S. aureus UAMS-1.
A)

B)

Figure 7: In-vitro UAMS-1 viability assay in synovial fluid. In (A) Bacterial viability assays were
performed with UAMS-1 in saline solution containing 20% synovial fluid from different donors with and
without the addition of 25M FeCl3. The CFU/mL of bacteria was determined at the time of inoculation
and 24 hours later in order to determine the percent survival from the inoculum N=2. In (B) a
combined analysis was performed with all synovial fluid donors included n=12. Statistical significance
was determined by Dunnett’s multiple comparison test where *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001. Dashed lines separate the results of each donor.

3.1.4 Synovial fluid can effectively kill multiple strains of S. aureus

Because this work previously found that USA300 was much more
resistant to synovial fluid than UAMS-1, the next goal was to determine
whether the synovial fluid is able to kill other strains of S. aureus. To test this
notion, bacterial viability assays were performed with the following S. aureus
strains: SH1000, RN6390, Newman and Newman sfasbn.
The synovial fluid in SH1000 demonstrated a significant decrease in the
CFU/ml compared to the control saline (***P<0.001). The addition of FeCl 3
did appear to improve bacterial viability in SH1000 strain, compared to the
synovial fluid samples without iron, although the increase was not
statistically significant. (Figure 8A). RN6390 was entirely eliminated in the
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synovial fluid, yet the addition of iron restored viability to the level of saline
alone control (Figure 8B). Furthermore, both Newman WT and the Newman

sfasbn mutant were killed in the synovial fluid and did not show improved
viability with the addition of FeCl3. Interestingly the sfasbn mutant which is
defective for iron acquisition had ~3 fold reduced viability compared to the
WT strain (Figure 8C-D). Taken together these data indicate that the
synovial fluid can kill multiple different S. aureus strains and the ability to
gather iron appears important for survival. However, it should be noted that
unlike before, the presence of iron did not significantly improve the bacterial
viability, likely attributable to a low number of replicates as most of the
strains are trending towards significance.
A)

B)
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C)

D)

Figure 8: Different strains viability assays in synovial fluid. Bacterial viability assays were
performed in saline solution containing 20% synovial fluid with and without additional of 25M FeCl3
iron. The initial CFU/mL of each samples was determined and the tubes were incubated for 24 hours
after which the sample was again plated to determine CFU/mL. (A) S. aureus SH1000 WT-strain N=3.
(B) S. aureus RN6390 WT-strain N=3. (C) S. aureus Newman WT-strain N=5. (D) S. aureus Newman
sfasbn mutant N=3. Statistical significance was determined by Bonferroni’s multiple comparison
test where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

3.1.5 Transferrin is responsible for sequestering iron in synovial fluid

The amount of iron available in the host environment is reduced by
sequestering proteins such as transferrin and lactoferrin (6). To determine if
one or both of these proteins is responsible for limiting access to iron in the
synovial fluid, we attempted to identify the presence of these proteins in
synovial fluid. A 12% sodium dodecyl sulfate polyacrylamide gel was
prepared and varying dilutions of synovial fluid were subjected to
electrophoresis. The gel showed a significant amount of protein around 75
kDa, the approximate size of transferrin or lactoferrin, is present in synovial
fluid (Figure 9). Either transferrin or lactoferrin could be responsible for
competing with bacteria to access any available iron in synovial fluid. To
determine the specific identity of the 75kDa protein samples were sent for
digestion

and

matrix

associated

laser

desorption

ionization-mass

spectrometry (MALDI-MS). This analysis confirmed that the 75kDa protein
identified in the synovial fluid is in fact transferrin (data not shown)
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supporting the previous observation that bacterial access to iron is restricted
in synovial fluid.

Figure 9: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) Synovial fluid
samples were diluted to a concentration range of 20%, 10%, 5% and 2.5% and 7L of each sample
was loaded onto a 12% sodium dodecyl sulfate polyacrylamide gel. The gel was run for 90 minutes at
150V and 500mA after which it was stained with InstantBlue to visualize the various proteins present
in the synovial fluid Samples were sent for Mass spectrometry at the department of biochemistry at
the University of Western Ontario. Boxed are the 75kDa marker (right) and the synovial fluid bands
identified at transferrin.

3.1.6 Synovial fluid containing high molecular weight proteins reduce
the bacterial growth more than filtrate synovial fluid

The next objective was to confirm the role of transferrin in restricting
bacterial growth in synovial fluid. In vitro growth experiments were performed
using synovial fluid that had been separated into fractions containing proteins
larger (with transferrin) and smaller (without transferrin) than 30kDa
(concentrate and filtrate respectively). The growth of various strains of S.
aureus was analyzed in the 2 fractions of filtered synovial fluid. It was found
that the synovial fluid concentrate, which would contain transferrin,
significantly reduced the growth of both UAMS-1 and RN6390 compared to the
filtrate which lacks transferrin (Figure 10). Importantly the Newman WT and
sfasbn strains did not have statistically significant differences between the
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filtrate and concentrate due to a low number of replicates, but the trend is clear
and the data are trending to significance. All together this demonstrates a
clear role for transferrin as a restrictive factor in synovial fluid that functions by
iron starving the bacteria sensitizing them to killing by some other unknown
factor.
A)

B)

C)

D)

Figure 10: Centricon filtered synovial fluid growth assay. 30kDa molecular weight cut off filter to
separate the fluid into fractions containing proteins above (concentrate) or below 30kDa (filtrate).
Dilution series of the filtrate and concentrate were inoculated with the various strains and incubated for
24 hours after which the samples were plated to determine the CFU/mL In (A) UAMS-1 and in (B),
RN6390 showed decreased CFU/mL in the concentrate. In (C), Newman WT and in (D) Newman
sfasbn there was no statically significant differences. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
N=3. Dashed lines indicate the inoculum CFU/mL.

3.1.7 The absence of GraS makes S. aureus more susceptible in
synovial fluid.

While the presence of transferrin in the synovial fluid explains the iron
limitation, it does not directly kill bacteria, so there must be another factor(s) at
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work causing the bacterial killing. To begin to investigate other factors that may
be responsible for bacterial killing we sought to determine the effect of synovial
fluid on a graS mutant of USA300. The graS is part of a two-component
regulatory system that is required by S. aureus for resistance against
antimicrobial peptides, meaning a graS mutant is highly sensitive to killing by
antimicrobial peptides. To this end bacterial viability assays were performed
with USA300 WT and graS. The WT USA300 showed no significant decrease
in CFU/mL over 24 hours in synovial fluid compared to the same strain in saline
alone (Figure 11). In contrast to WT, the graS mutant was much more
sensitive to killing by the synovial fluid and had a 2-log decrease compared to
the same strain in saline alone (**P<0.01 Figure 11). This finding suggests that
there are likely antimicrobial peptides present in the synovial fluid that result in
bacterial killing.

Figure 11: The absent of GraS render S. aureus more susceptible. Bacterial viability assays were
performed for the graS mutant and strain USA300 WT in 50% synovial fluid compared with saline
solution alone. The CFU/mL of bacteria was determined immediately after inoculating each strain and
again after 24 hour incubation. Percent survival was determined by dividing the CFU/mL at 24 hours
by the CFU/mL inoculated for the corresponding sample. **P<0.01 N=3.
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3.2 ANIMAL MODEL OF S. AUREUS PERIPROSTHETIC JOINT
INFECTION (pilot study)
3.2.1 In vivo bioluminescence imaging is able to monitor an animal
model of periprosthetic infection.

In vivo bioluminescence images were made at 7, 14, 21, 28, 35, 42
postoperative days (Figure 12). The Relative Light Units (RLU) emitted by S.
aureus from the mice knee joint were decreasing progressively over the
days. Although the WT strain demonstrated better signal in the first three
weeks, it decreased quickly after post-operative day 21. In contrast, the
purR::ΦΝΣ and fhuCBG::ery strains kept relatively stable after postoperative day 21 (Figure 13).
A)

B)

C)

D)
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E)

F)

Figure 12: In vivo bioluminescence imaging in animal model of PJI. (A) Postoperative day 7. (B)
Postoperative day 14. (C) Postoperative day 21. (D) Postoperative day 28. (E) Postoperative day 35. (F)
Postoperative day 42.

Figure 13: Relative light units emitted from mouse knee over the time.

3.2.2 Bacterial burden was found in periprosthetic soft tissues and
implants.

We next sought to determine the bacterial burden in periprosthetic soft
tissues and implants recovered. For this, in vitro bacterial growth analyses
were performed in TSB and TSB with chloramphenicol. The growth on
chloramphenicol allows us to determine the bacteria recovered still carry the
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bioluminescence genes and the associated chloramphenicol resistance
marker. After 24 hours incubation at 37°C, the number of CFU/mL were
determined.
All bone tissue samples demonstrated the presence of bacterial burden.
In contrast, the results obtained from the culture of the implants showed
variability, with bacteria recovered in only two samples, and with no clear
association with a particular bacterial strain.
Although these findings demonstrate the feasibility of the model, in both
bioluminescent tracking and recovery of bacteria, the size of the pilot study
does not allow for statistical differences to be calculated.

Figure 14: In vitro bacterial growth analysis allowed to determine the presence of bacteria in
bone tissues and implants recovered from the animals.

3.2.3 Correlation of CFU/mL to RLU and construct stability

Our next goal was to determine whether there was a correlation
between the RLU emitted from the mouse knee with the number of bacteria
recovered from the bone tissues and implants. In WT strain and purR::ΦNΣ
mutant strain there was a clear correlation, with the strength of the signal
relating to the number of bacteria recovered. In contrast, fhuCBG::ermC
mutant strain did not emit bioluminescence signal on day 42, therefore we
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were not able to observe a correlation in this mutant even though there was
bacterial growth in the recovered bone tissues samples.
Taken

together,

these

findings

demonstrate

the

successful

establishment of an animal model of PJI, which allows the temporal
observation of disease progression and gives the ability to track different
bacterial mutants. This is a powerful tool that will allow us to further study
the specific S. aureus factors involved in the establishment and development
of PJI and inform the design of novel preventative techniques. Nevertheless,
the findings demonstrated here were a pilot experiment, and further
conclusions will require the use of a higher number of animals for the
different conditions tested.

Figure 15: Correlation of CFU/mL to RLU.
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CHAPTER

4

DISCUSSION AND FUTURES DIRECTIONS

The number of arthroplasty procedures performed every year is
increasing, as a result of this, there is an anticipated increase in revision
arthroplasty (24). Periprosthetic joint infection (PJI) is the leading cause of
revision surgery, and is the most challenging complication after total joint
replacement (23). Infections remain a challenge for both patients and
surgeons to treat and occur in approximately 1% of cases.
S. aureus is an opportunistic human bacterial pathogen responsible for
nosocomial and community-associated infections (80). Its genetic plasticity
has facilitated the evolution of many virulent and drug-resistant strains,
presenting a major and constantly changing clinical challenge. Despite this,
there has been relatively little research regarding the pathogenic
mechanisms in synovial fluid. This study demonstrated that S. aureus has a
high in vitro sensitivity in synovial fluid. Synovial fluid can not only reduce
bacterial growth, it can also kill bacteria.
It's still not clearly understood what the composition of the synovial fluid
is of patients about to undergo joint replacements (67). Recent studies
suggest that the synovial fluid may contribute to a joint’s innate defense
against certain microbial infections (68). Iron is an essential micronutrient
used by bacteria for their growth. Supported by the observation that the
additional iron significantly increased bacterial growth compared to the
control specimen, we were able to confirm that iron restriction is one of the
mechanisms used for the host to prevent bacterial growth in synovial fluid. In
addition, in our in vitro assays, we could observe that limited access to iron
not only prevented bacterial growth, it was even killing bacteria. These
findings were present in different strains of S. aureus.
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As previously noted, iron is essential for basic bacterial physiologic
processes such as electron transport or nucleotide synthesis (6). However,
free iron is virtually unavailable in host environments. Human molecules,
such as protoporphyrins (heme) or proteins (ferritin, transferrin, lactoferrin,
hemoglobin, etc.) sequester most of the iron from the extracellular space,
competing with the bacteria for it (88). These glycoproteins have a high
affinity for free iron. S. aureus indirectly steals iron from lactoferrin or
transferrin through the production of siderophores. Siderophores are
secreted small molecules that have an extremely high affinity for iron and
outcompete host iron-binding proteins. Siderophore-iron complexes are
recognized by cognate receptors on the bacterial surface permitting the theft
of iron from lactoferrin or transferrin (89). The synovial fluid composition is
still not well known. Through our in-vitro experiments, we could confirm a
significant amount of protein around 75 kDa, the approximate size of
transferrin or lactoferrin, is present in synovial fluid. After matrix associated
laser desorption ionization-mass spectrometry mass spectrometry (MALDIMS), we confirmed that the 75kDa protein identified in the synovial fluid is in
fact transferrin, which could be responsible for competing with bacteria to
access any available iron in synovial fluid. Furthermore, after different
assays using synovial fluid that had been separated into fractions containing
proteins larger (with transferrin) and smaller (without transferrin) than 30kDa
(concentrate and filtrate respectively) we were able to demonstrate that the
synovial fluid concentrate significantly reduced the growth of different strains
of S. aureus. This finding speaks to clear role of transferrin as a restrictive
factor in synovial fluid that functions by either competing the bacteria for
iron, or sensitizing them and killing by some other unknown factor.
While the presence of transferrin in the synovial fluid explains the iron
limitation, it does not directly kill bacteria, so there must be another factor(s)
at work causing the bacterial killing. To begin to investigate other factors that
may be responsible for bacterial killing, we were able to determine the effect
of synovial fluid on a GraS mutant of USA300. The GraS contributes to S.
aureus survival in vivo in the acute stages of systemic infection and is part of
a two-component regulatory system that is required by S. aureus for
resistance against antimicrobial peptides, meaning a GraS mutant is highly
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sensitive to killing by antimicrobial peptides (16). Consistent with our
observations, there are likely antimicrobial peptides present in the synovial
fluid that result in bacterial killing. However more work is needed as the
specific peptide(s) in the synovial fluid have not been identified and there
may still be other factors that contribute to the restriction and/or killing of S.
aureus in synovial fluid.
In light of limited treatment successes, persistence of poor patient
outcomes, and an increasing number of infections, we need to develop
animal models to enhance our fundamental understanding and treatment of
PJI.

Once

established,

such

models are likely to

transform our

understanding of the pathogenesis of PJI and lead to novel treatments (74).
An important factor to consider when investigating mechanisms pertinent to
human infection is whether animal models accurately reflect clinical features
of human disease (90). Currently it is possible to develop non-invasive in
vivo images of specific molecular and cellular mechanisms to optimize gene
and drug therapy, visualize the effects of medications and assess the
progression of the disease (76). Furthermore, obtaining in vivo longitudinal
images of the same animal model at multiple time points would avoid the
sacrifice of a large number of experimental animals; in these systems, the
animal acts as its own control and the dynamic data show the progressive
biological changes and the therapeutic response (78). Given the diversity of
S. aureus strains and their propensity to cause community- or hospitalacquired infections, we performed a preliminary animal model with three
different S. aureus strains (USA300 wild-type, fhuCBG::ermC mutant strain,
and purR::ΦNΣ mutant strain). Our findings allowed us to establish an
animal model of PJI and observe the progression of the infection over the
several weeks. Although this model represents only preliminary work, and a
greater number of repetitions is needed to obtain statistically significant
conclusions, we have managed to create a successful animal model of
periprosthetic infection that allowed us to follow the infection in vivo and
obtain a correlation between the number of recovered bacteria from the
bone tissues and the relative light units emitted from the knee of the mouse.
This model will serve as the foundation for future work with animal models of
periprosthetic infection.
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In summary, while the observations in this thesis are expected to
generate significant interest, there is still a lot of work to be completed. It
was demonstrated that the synovial fluid is able to prevent and even kill
different S. aureus strains through the presence of transferrin which
competes with the bacteria for the extracellular iron, but clearly more work is
needed as there may still be other factors that contribute to the restriction
and/or killing of S. aureus in synovial fluid. We found there are likely
antimicrobial peptides present in the synovial fluid that result in bacterial
killing, however, the specific peptide(s) in the synovial fluid have not been
identified yet. Lastly, we created a successful animal model of periprosthetic
joint that will serve as the basis of new models to solve the most challenging
clinical problem facing arthroplasty patients and surgeons from the standpoint of treatment and clinical outcomes.
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